Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus PRAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus PRAZOSIN HYDROCHLORIDE.
ALFUZOSIN HYDROCHLORIDE vs PRAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Prazosin is a quinazoline derivative that acts as a selective, competitive antagonist at postsynaptic alpha-1 adrenergic receptors. It blocks the binding of norepinephrine, thereby inhibiting vasoconstriction and reducing peripheral vascular resistance, leading to decreased blood pressure. It also relaxes smooth muscle in the prostate and bladder neck, improving urine flow. Additionally, it may block alpha-1 receptors in the central nervous system, reducing sympathetic outflow and ameliorating nightmare-related symptoms in PTSD.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
1 mg orally 2-3 times daily, titrated up to 20 mg/day in divided doses for hypertension; for benign prostatic hyperplasia, 0.5-1 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Terminal elimination half-life: 2-3 hours. However, antihypertensive effect persists for up to 24 hours due to prolonged receptor binding, allowing once-daily dosing.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Primarily hepatic metabolism (demethylation and conjugation); <10% unchanged in urine; 90% eliminated via bile/feces.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker